Business Wire·Nov 10, 2026, 9:04 AM ET

CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research

CVM

CEL-SCI Corporation announced its Chief Scientific Officer Dr. Eyal Talor received a second invitation to deliver a keynote address at the 3rd Global Congress on Otolaryngology, Head and Neck Surgery in Lisbon, Portugal, scheduled for June 9-10, 2027.
Dr. Talor's upcoming presentation will cover findings from the IT-MATTERS Phase 3 study regarding Multikine neoadjuvant immunotherapy & the use of biomarkers to identify patients likely to benefit.
The new invitation follows Dr. Talor's recent keynote speech in Rome on October 26, 2026, both occurring after peer-reviewed publications of the company's research.
Multikine is described as the first pre-surgery treatment to significantly increase overall survival for resectable locally advanced head and neck squamous cell carcinoma patients in decades.
The completed 928-patient IT-MATTERS Phase 3 study identified disease & tumor biomarkers to select target patients, showing a 73% 5-year survival rate for this group compared to 45% with standard care alone.
In the target patient population, Multikine treatment halved the risk of death from 55% to 27% compared to standard of care.
CEL-SCI is applying the identified biomarker-based selection method prospectively in a new 212-patient Registration Study designed with approximately 97% statistical power to detect the observed survival effect.
Multikine (Leukocyte Interleukin, Injection) is an investigational therapy that has been administered to over 740 patients & holds FDA Orphan Drug designation for this indication.
The company operates in Vienna, Virginia & near Baltimore, Maryland.
The press release includes standard forward-looking statement disclaimers regarding regulatory approvals, manufacturing, & capital raising risks.